- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00777673
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
January 3, 2013 updated by: University of Tennessee Cancer Institute
Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer
The purpose of this study is to determine how well this combination of chemotherapy drugs works with bevacizumab in eliminating primary tumor in the breast prior to surgery(pathological complete response or pCR in the breast).
Bevacizumab is a drug that works by blocking new blood vessel formation by the tumor cells.
Giving chemotherapy and bevacizumab before surgery may allow for lesser amount of breast tissue to be removed.
To be able to predict in the future which patients are more likely to get pCR to this drug combination, specialized tests on tumor tissue will be performed.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- The West Clinic
-
Memphis, Tennessee, United States, 38104
- University of Tennessee Cancer Institute
-
-
Texas
-
Ft. Worth, Texas, United States, 76104
- The Center for Cancer and Blood Disorders
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patient must be female and ≥ 18 years of age.
- ECOG performance status 0 or 1
- Diagnosis of invasive adenocarcinoma of the breast must be made by a core needle biopsy. ER, PR and HER2 must be available on the initial diagnostic biopsy and must be negative. HER2 negativity is defined as 0 or 1+ staining on IHC or documented non amplification by FISH. Patients with 2+ staining on IHC must be non amplified by FISH. Patients with tumors determined to be 3+ on IHC or amplified for HER2 by FISH are ineligible.
- Primary breast tumor must be ≥ 2cm and meet RECIST criteria for palpable measurable disease. Two synchronous tumors in the same breast are allowed, but one of them must be ≥ 2 cm and clinically palpable at baseline.
- Patients must agree to submission of two additional core biopsy specimens for correlative studies.
- A baseline cardiac ejection fraction ≥ lower limit of normal (LLN) for the imaging facility must be obtained within 21 days of study entry.
- EKG with no acute or significant abnormalities, obtained within 21 days of study entry.
- Adequate hematologic, renal and hepatic function (ANC ≥ 1,500, platelet count ≥100,000, hemoglobin > 10, serum creatinine ≤ upper limit of nor (ULN) for the institution, total bilirubin ≤ 1.5 mg/dL, and AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 2 x ULN) obtained within 21 days of study entry.
- Urine protein/urine creatinine (UPC) ratio must be < 1.0. Patients discovered to have a UPC > 1.0 at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible.
- Patients with reproductive potential must use an effective method of contraception to avoid pregnancy for the duration of the trial.
- If female of child bearing potential, pregnancy test must be documented as negative.
Exclusion Criteria:
- Patients with documented metastatic disease are ineligible.
- Patients with tumors clinically staged as T4, including inflammatory cancer are ineligible.
- Patients with ipsilateral cN2b or cN3 disease are ineligible. (cN1 or cN2a disease are eligible)
- Patients who have had any prior chemotherapy, radiation therapy, hormonal or biologic therapy for the currently diagnosed breast cancer prior to study entry are ineligible.
- Therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention. (Patients are eligible only if these medications are discontinued prior to randomization.)
- Patients with any major surgery, open biopsy or significant traumatic injury within 28 days prior to study entry or anticipation of major surgery during the study other than their definitive breast surgery are ineligible.
- Patients with surgical axillary staging prior to study entry are ineligible. FNA of clinically palpable nodes is permissible. Although not recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for patients with clinically negative axillary nodes is permissible.
- Patients must not have a significant history of cardiac disease (congestive heart failure New York Heart association (NYHA) Grade II or greater, uncontrolled hypertension {defined as BP > 150/90 on antihypertensive therapy. Patients with hypertension that is well controlled on medication are eligible.} unstable angina, myocardial infarction or ventricular arrhythmias requiring medications within 12 months prior to study entry. Prior history of hypertensive crisis or hypertensive encephalopathy.
- Patients with a prior history of TIA, CVA or other arterial thrombotic events prior to study entry are ineligible.
- Patients with significant vascular disease (e.g., aortic aneurysm, aortic dissection) or symptomatic peripheral vascular disease are ineligible.
- Patients with any significant non traumatic bleeding within 6 months prior to study entry are ineligible.
- Patients with serious or non healing wound, skin ulcers or incompletely healed bone fractures are ineligible.
- Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment are ineligible.
- Patient with known bleeding diathesis or coagulopathy are ineligible. Patients on a stable dose of warfarin with a therapeutic INR between 2 and 3 are eligible.
- Patients with sensory or motor neuropathy ≥ grade 2 (NCI Common toxicity criteria adverse events version 3.0) are ineligible.
- No prior malignancy is allowed with the exception of treated basal or squamous cell carcinomas of the skin, cervical cancer in situ, or any other cancer provided that the patient has been disease free for ≥ 5 years.
- Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude treatment with any of the treatment regimens or would prevent required follow-up.
- Patients with known infection with HIV, HBV or HCV are ineligible.
- Patients with psychosocial conditions that preclude medical follow up and compliance with the treatment protocol are ineligible.
- Patients with known hypersensitivity to any of the study drugs are ineligible.
- Administration of any investigational agents within 30 days before study entry.
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pathological complete response (pCR) in the breast
Time Frame: No interim efficacy analysis is planned. It is anticipated that the definitive analysis would be performed approximately 3 years after initiation of accrual (2 years to accrue 60 patients plus one additional year of follow up)
|
No interim efficacy analysis is planned. It is anticipated that the definitive analysis would be performed approximately 3 years after initiation of accrual (2 years to accrue 60 patients plus one additional year of follow up)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of near pCR/pCR of breast, axillary Ns & non axillary SNs cRR with nab-paclitaxel + carbo with bev cRR post neoadj Tx Rate of breast conserving surgery Safety & tolerability Disease free survival Identify gene(s) that may predict pCR to Tx
Time Frame: Approximately 3 years from study initiation
|
Approximately 3 years from study initiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jasgit C. Sachdev, MD, University of Tennessee Cancer Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Anticipated)
January 1, 2013
Study Completion (Anticipated)
October 1, 2013
Study Registration Dates
First Submitted
October 20, 2008
First Submitted That Met QC Criteria
October 21, 2008
First Posted (Estimate)
October 22, 2008
Study Record Updates
Last Update Posted (Estimate)
January 4, 2013
Last Update Submitted That Met QC Criteria
January 3, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Carboplatin
- Paclitaxel
- Bevacizumab
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- BRE 01-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
Clinical Trials on Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
The Netherlands Cancer InstituteActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and UreterUnited States
-
Commissie Voor Klinisch Toegepast OnderzoekUnknownLung CancerNetherlands
-
National Cancer Centre, SingaporeTerminated
-
Hunan Cancer HospitalRecruiting
-
M.D. Anderson Cancer CenterLyvgen Biopharma Holdings LimitedRecruitingGastric Cancer | Metastatic Uveal Melanoma | Metastatic Head and Neck Carcinoma | Metastatic Hepatocellular Carcinoma | Metastatic Ovarian Carcinoma | Metastatic Soft Tissue Sarcoma | Metastatic Esophageal | Metastatic HPV Related Solid TumorsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Shanghai Henlius BiotechNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedEndometrial CancerUnited States